{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:35:27Z","timestamp":1786995327301,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018787","name":"Novartis Pharma AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018787","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.oret.2025.05.030","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T19:45:17Z","timestamp":1748893517000},"page":"1175-1186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["TALON Phase IIIb Study: 32-Week Primary Results of Brolucizumab Using Treat and Extend for Neovascular Age-Related Macular Degeneration"],"prefix":"10.1016","volume":"9","author":[{"given":"Carl","family":"Regillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5126-045X","authenticated-orcid":false,"given":"Peter K.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0348-5096","authenticated-orcid":false,"given":"Peter J.","family":"Kertes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gillies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Maio-Twofoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegbert","family":"Guenther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8019-9272","authenticated-orcid":false,"given":"Frank G.","family":"Holz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2025.05.030_bib1","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.oret.2025.05.030_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2019-000398","article-title":"Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review","volume":"4","author":"Khanna","year":"2019","journal-title":"BMJ Open Ophthalmol"},{"key":"10.1016\/j.oret.2025.05.030_bib3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ajo.2011.10.016","article-title":"Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010","volume":"153","author":"Bloch","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2025.05.030_bib4","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1001\/archophthalmol.2011.2480","article-title":"Impact of availability of anti-vascular endothelial growth factor therapy on visual impairment and blindness due to neovascular age related macular degeneration","volume":"130","author":"Campbell","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2025.05.030_bib5","article-title":"Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration","volume":"5","author":"Li","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.oret.2025.05.030_bib6","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","article-title":"Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: a randomized controlled trial","volume":"37","author":"Ohji","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.oret.2025.05.030_bib7","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1016\/j.ophtha.2015.08.009","article-title":"Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results","volume":"122","author":"Wykoff","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.05.030_bib8","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ajo.2017.06.002","article-title":"Treat-and-extend therapy using aflibercept for neovascular age-related macular degeneration: a prospective clinical trial","volume":"180","author":"DeCroos","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2025.05.030_bib9","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.oret.2016.12.004","article-title":"Randomized trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: 2-year results of the TREX-AMD Study","volume":"1","author":"Wykoff","year":"2017","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2025.05.030_bib10","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ophtha.2018.11.025","article-title":"Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen: FLUID study 24-month results","volume":"126","author":"Guymer","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.05.030_bib11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2017.07.014","article-title":"Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study","volume":"125","author":"Silva","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.05.030_bib12","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1001\/jamaophthalmol.2018.6776","article-title":"Effect of ranibizumab and aflibercept on best-corrected visual acuity in treat-and-extend for neovascular age-related macular degeneration: a randomized clinical trial","volume":"137","author":"Gillies","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2025.05.030_bib13","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.ophtha.2019.01.013","article-title":"Canadian treat-and-extend analysis trial with ranibizumab in patients with neovascular age-related macular disease: one-year results of the randomized Canadian treat-and-extend analysis trial with ranibizumab study","volume":"126","author":"Kertes","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.05.030_bib14","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.2147\/OPTH.S92548","article-title":"Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey","volume":"9","author":"Varano","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2025.05.030_bib15","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/jamaophthalmol.2021.1660","article-title":"Defining nonadherence and nonpersistence to anti-vascular endothelial growth factor therapies in neovascular age-related macular degeneration","volume":"139","author":"Okada","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2025.05.030_bib16","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","article-title":"Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration","volume":"99","author":"Holz","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2025.05.030_bib17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/vision3030041","article-title":"Treat and extend treatment interval patterns with anti-VEGF therapy in nAMD patients","volume":"3","author":"Skelly","year":"2019","journal-title":"Vision (Basel)"},{"key":"10.1016\/j.oret.2025.05.030_bib18","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.ophtha.2019.12.031","article-title":"Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration","volume":"127","author":"Nguyen","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.05.030_bib19","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.ophtha.2017.03.057","article-title":"Brolucizumab versus aflibercept in participants with neovascular age-related macular segeneration: a randomized trial","volume":"124","author":"Dugel","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.05.030_bib20","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.05.030_bib21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","article-title":"HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration","volume":"128","author":"Dugel","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.05.030_bib22","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ophtha.2022.04.028","article-title":"MERLIN: phase 3a, multicenter, randomized, double-masked trial of brolucizumab in participants with neovascular age-related macular degeneration and persistent retinal fluid","volume":"129","author":"Khanani","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.05.030_bib23","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","article-title":"Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER","volume":"128","author":"Mon\u00e9s","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.05.030_bib24","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","article-title":"Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab","volume":"127","author":"Baumal","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.05.030_bib25","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.oret.2020.09.020","article-title":"Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after brolucizumab treatment","volume":"5","author":"Baumal","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2025.05.030_bib26","series-title":"Proposed best practice for Irish ophthalmologists: monitoring of patients following intra-vitreal brolucizumab therapy","first-page":"1","author":"Kilmartin","year":"2021"},{"key":"10.1016\/j.oret.2025.05.030_bib27","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s00347-021-01321-8","article-title":"Intraocular inflammation with brolucizumab use: patient management-diagnosis-therapy","volume":"118","author":"Holz","year":"2021","journal-title":"Ophthalmologe"},{"key":"10.1016\/j.oret.2025.05.030_bib28","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/s41433-022-02008-3","article-title":"The changing landscape for the management of patients with neovascular AMD: brolucizumab in clinical practice","volume":"36","author":"Pearce","year":"2022","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2025.05.030_bib29","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.oftal.2022.02.006","article-title":"Guidance on brolucizumab management recommendations","volume":"97","author":"Fonollosa","year":"2022","journal-title":"Arch Soc Esp Oftalmol (Engl Ed)"},{"key":"10.1016\/j.oret.2025.05.030_bib30","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1159\/000526703","article-title":"The importance of imaging to identify early signs of intraocular inflammation: expert opinion for brolucizumab","volume":"245","author":"Sadda","year":"2022","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.oret.2025.05.030_bib31","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1097\/IAE.0000000000003556","article-title":"A consensus on risk mitigation for brolucizumab in neovascular age-related macular degeneration: patient selection, evaluation, and treatment","volume":"42","author":"Holz","year":"2022","journal-title":"Retina"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653025002672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653025002672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T19:42:02Z","timestamp":1772048522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653025002672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2468653025002672"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2025.05.030","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TALON Phase IIIb Study: 32-Week Primary Results of Brolucizumab Using Treat and Extend for Neovascular Age-Related Macular Degeneration","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2025.05.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}]}}